Tudor Investment Corp ET AL Makes New Investment in Bausch + Lomb Corporation $BLCO

Key Points

• Tudor Investment Corp opened a new position in Bausch + Lomb, buying 149,270 shares valued at about $2.25 million in the third quarter.
• Insiders increased stakes: CEO Brent L. Saunders and EVP Robert D. Bailey each purchased roughly 14.7k and 14.6k shares on March 6 (around $17.14–$17.15/share), and insiders have bought 33,300 shares in the past 90 days.
• Bausch + Lomb reported $0.32 EPS (missing estimates of $0.35) with revenue of $1.41 billion—up 9.8% year-over-year—and analysts hold a consensus "Hold" rating with an average price target of $18.25, though several firms have raised targets (Citigroup to $21).

Tudor Investment Corp ET AL purchased a new position in Bausch + Lomb Corporation (NYSE:BLCO - Free Report) in the third quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 149,270 shares of the company's stock, valued at approximately $2,249,000.

A number of other institutional investors also recently made changes to their positions in the stock. Woodline Partners LP lifted its stake in shares of Bausch + Lomb by 0.5% in the 1st quarter. Woodline Partners LP now owns 312,823 shares of the company's stock worth $4,536,000 after acquiring an additional 1,436 shares during the period. Northwestern Mutual Wealth Management Co. lifted its stake in shares of Bausch + Lomb by 729.3% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 2,322 shares of the company's stock worth $30,000 after acquiring an additional 2,042 shares during the period. Fountainhead AM LLC lifted its stake in shares of Bausch + Lomb by 17.8% in the 3rd quarter. Fountainhead AM LLC now owns 17,429 shares of the company's stock worth $263,000 after acquiring an additional 2,629 shares during the period. Jones Financial Companies Lllp lifted its stake in shares of Bausch + Lomb by 55.3% in the 3rd quarter. Jones Financial Companies Lllp now owns 9,112 shares of the company's stock worth $132,000 after acquiring an additional 3,246 shares during the period. Finally, Clearline Capital LP lifted its stake in shares of Bausch + Lomb by 0.4% in the 3rd quarter. Clearline Capital LP now owns 917,042 shares of the company's stock worth $13,820,000 after acquiring an additional 3,532 shares during the period. 11.07% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, EVP A Robert D. Bailey purchased 14,600 shares of the business's stock in a transaction dated Friday, March 6th. The shares were acquired at an average price of $17.15 per share, for a total transaction of $250,390.00. Following the completion of the acquisition, the executive vice president directly owned 231,890 shares of the company's stock, valued at $3,976,913.50. The trade was a 6.72% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Brent L. Saunders purchased 14,700 shares of the business's stock in a transaction dated Friday, March 6th. The shares were purchased at an average price of $17.14 per share, for a total transaction of $251,958.00. Following the acquisition, the chief executive officer directly owned 966,575 shares of the company's stock, valued at $16,567,095.50. This trade represents a 1.54% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have bought 33,300 shares of company stock worth $570,868 over the last 90 days. 0.76% of the stock is owned by company insiders.

Bausch + Lomb Stock Down 0.0%

BLCO stock opened at $16.47 on Friday. Bausch + Lomb Corporation has a 12 month low of $10.45 and a 12 month high of $18.92. The firm has a 50 day simple moving average of $16.87 and a 200 day simple moving average of $16.38. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.55 and a quick ratio of 1.04. The firm has a market cap of $5.87 billion, a PE ratio of -16.15, a P/E/G ratio of 0.69 and a beta of 0.65.

Bausch + Lomb (NYSE:BLCO - Get Free Report) last released its quarterly earnings results on Wednesday, February 18th. The company reported $0.32 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.35 by ($0.03). Bausch + Lomb had a negative net margin of 7.06% and a positive return on equity of 2.77%. The firm had revenue of $1.41 billion for the quarter, compared to analyst estimates of $1.38 billion. During the same quarter in the prior year, the firm earned $0.25 EPS. The firm's revenue was up 9.8% compared to the same quarter last year. Equities research analysts forecast that Bausch + Lomb Corporation will post 0.74 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the stock. Citigroup upped their price target on shares of Bausch + Lomb from $20.00 to $21.00 and gave the stock a "buy" rating in a research note on Thursday, February 19th. HC Wainwright increased their target price on shares of Bausch + Lomb from $17.00 to $20.00 and gave the company a "buy" rating in a research note on Monday, February 23rd. Wall Street Zen lowered shares of Bausch + Lomb from a "buy" rating to a "hold" rating in a research note on Saturday, February 21st. Barclays increased their target price on shares of Bausch + Lomb from $17.00 to $20.00 and gave the company an "equal weight" rating in a research note on Thursday, February 19th. Finally, Evercore set a $18.00 target price on shares of Bausch + Lomb and gave the company an "in-line" rating in a research note on Monday, January 5th. Four investment analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, Bausch + Lomb has an average rating of "Hold" and a consensus price target of $18.25.

About Bausch + Lomb

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.